POSTERS AND PRESENTATIONS
LUM-201
IMPE 2023
“Dose-dependent Increase in GH AUC0-12h with LUM- 201 in Idiopathic Pediatric GH Deficiency from the Interim Analysis Data of the OraGrowtH212 Trial”
Cassorla F, MD; Román R, MD; Johnson M, PhD; Smith C, MS; Avila A, RN; Iñiguez G, PhD; Baier I, MD; Said D, RN; Karpf DB, MD; McKew JC, PhD; Thorner M, MB BS, DSc
Disclosures
Dr. Cassorla is an investigator for clinical studies with LUM-201 at the University of Chile (Sponsor – Lumos Pharma, Inc.) and has previously acted as a consultant for Debiopharm, Pfizer, Merck, Novo Nordisk and Sandoz.
LUM-201 is an investigational compound and is not approved for use by the FDA or any other regulatory agency. Some of the slides in this presentation are derived or copied from corporate presentations previously given by Lumos Pharma, Inc. These slides are used with permission.
View the Presentation
“LUM-201 in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD) Interim Analysis on Baseline Demographics, Safety Profile and 6 month Annualized Height Velocity (AHV) from the OraGrowtH210 Trial”
Alison Lunsford1, Beata Wikiera2, Andrew Dauber3, Beata Pyrzak4, Artur Bossowski5, Michael Tansey6, Elzbieta Petriczko7, Renata Stawerska8,9, Sasigarn Bowden10, Matthew Feldt11, Michael Everett Gottschalk12, Monica Marin13, Sunil Nayak14, Bhuvana Sunil15, Elzbieta Moszczynska16, David Repaske17, Leslie Soyka18, John Fuqua19, Oscar Escobar20, Deborah Bowlby21, Patricia Y. Fechner22, Esko Wiltshire23, Mark Harris24, Kupper Wintergest25, Antony R Lafferty26, Bradley S Miller27, Peter Simm28, Aleksandra Bruchey29, Christopher Smith29, David B Karpf29, John C McKew29, Michael O Thorner29
1Texas Tech HSC Amarillo, Amarillo, USA. 2Klinika Endokrynologii i Diabetologii Wieku Rozwojowego UM, Wrocław, Poland. 3Children’s National Hospital, Washington DC, USA. 4Department of Pediatric and Endocrinology Medical University of Warsaw, Warsaw, Poland. 5Department of Pediatric Endocrinology and Diabetes with a Cardiology Division. Medical University in Białystok, Poland, Białystok, Poland. 6University of Iowa, Iowa City, USA. 7Sonomed Clinic, Szczecin, Poland. 8Polish Mother’s Memorial Hospital – Research Institute, Łódź, Poland. 9Medical University of Lodz, Łódź, Poland. 10Nationwide Children’s Hospital, Columbus, USA. 11Children’s Mercy Hospital and Clinics, Kansas City, USA. 12University of California San Diego/Rady Children’s Hospital, San Diego, USA. 13Oklahoma Children’s Hospital OU Health, Oklahoma City, USA. 14Pediatric Endocrine Associates, Greenwood Village, USA. 15Mary Bridge Children’s Hospital and Health Center, Tacoma, USA. 16Memorial Institute Children’s Health Center, Warsaw, Poland. 17University of Virginia, Charlottesville, USA. 18UMass Chan Medical School, Worcester, USA. 19Indiana University School of Medicine, Indianapolis, USA. 20UPMC Children’s Hospital of Pittsburgh, Pittsburgh, USA. 21Medical University of South Carolina, Charleston, USA. 22Seattle Children’s/University of WA, Seattle, USA. 23University of Otago Wellington, Wellington, New Zealand. 24Queensland Children’s Hospital, South Brisbane, Australia. 25University of Louisville, Louisville, USA. 26Canberra Hospital and Australian National University Medical School, Canberra, Australia. 27University of Minnesota Medical School, Minneapolis, USA. 28Royal Children’s Hospital, Melbourne, Australia. 29Lumos Pharma, Austin, USA
View the Poster
ENDO 2021
“LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency”
George Bright, MD, Roy Smith, PhD, Michael O. Thorner, MB, BS, DSc.
Lumos Pharma, Austin, TX, USA.
Disclosures
G. Bright: Consulting Fee; Self; Lumos Pharma. R. Smith: Consulting Fee; Self; Lumos Pharma. M.O. Thorner: Consulting Fee; Self; Lumos Pharma. Stock Owner; Self; Lumos Pharma.
View the Poster Presentation |
View the Poster |
 |